Comparative analysis of PD-L1 and CTLA-4 expression in brain metastases and primary tumors.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024132

Enrollment

Registered

2021-04-30

Start date

2021-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C79.3

Interventions

Group 1: Patients suffering from cerebral metastases who underwent tumor resection or biopsy. Retrospective manner, immunogistochemistry for PD-L1 and CTLA-4 after informed consent.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: availabe tumor tissue from both sites. informed consent.

Exclusion criteria

Exclusion criteria: no tissue available. missing informed consent.

Design outcomes

Primary

Measure	Time frame
Differences in PD-L1 and CTLA-4 expression brain metastases vs. primary tumor.	—

Countries

Germany

Contacts

Public ContactStephanie Jünger

Klinik für Allgemeine NeurochirurgieUniklinik Köln

stephanie.juenger@uk-koeln.de00492214784550

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026